Butterfly Network, Inc. Class A Common Stock (BFLY)
2.2050
-0.0250 (-1.12%)
NYSE · Last Trade: Oct 27th, 3:18 PM EDT
Detailed Quote
Previous Close
2.230
Open
2.280
Bid
2.200
Ask
2.210
Day's Range
2.190 - 2.290
52 Week Range
1.320 - 4.980
Volume
2,616,438
Market Cap
63.81M
PE Ratio (TTM)
-2.534
EPS (TTM)
-0.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
6,343,672
Chart
About Butterfly Network, Inc. Class A Common Stock (BFLY)
Butterfly Network Inc is a digital health company that specializes in transforming the field of medical imaging through its innovative ultrasound technology. Utilizing a unique handheld, pocket-sized ultrasound device, the company aims to make ultrasound accessible and affordable, allowing healthcare professionals to perform imaging anytime and anywhere. By incorporating artificial intelligence into its platform, Butterfly Network enhances the capabilities of its devices, offering real-time diagnostics and improved decision-making for clinicians. The company is dedicated to improving patient outcomes by democratizing healthcare access and streamlining the imaging process in various medical settings. Read More
In a monumental shift for the healthcare industry, machine learning (ML) applications are rapidly being integrated into triage systems, promising to redefine how patients are prioritized and managed. As of October 2025, these intelligent systems are moving beyond experimental phases, demonstrating significant immediate impact in alleviating emergency department (ED) overcrowding, enhancing patient safety, and optimizing [...]
Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound, today announced it has achieved certification for ISO 27001, the world’s leading standard for information security management systems, published by the International Organization for Standardization (ISO) in partnership with the International Electrotechnical Commission (IEC). This globally recognized accreditation reinforces Butterfly’s commitment to maintaining the highest standards of cybersecurity and data protection requirements.
NetworkNewsWire Editorial Coverage : Artificial intelligence (“AI”) continues to transform healthcare innovation, with medical imaging emerging as one of its most promising frontiers. In breast cancer detection, where early identification often determines patient outcomes, AI-powered imaging technologies are pushing beyond the technical constraints of traditional mammography, tomosynthesis, and MRI. Globally, breast cancer remains the most frequently diagnosed cancer among women. The World Health Organization (“WHO”) reported that more than 2.3 million women were diagnosed, with approximately 670,000 losing their lives to the disease in 2022. In the United States, the American Cancer Society (“ACS”) estimates that 316,950 new invasive breast cancer cases will be identified this year alone. This urgent demand for faster, more accurate diagnostic tools is driving a surge of innovation across the imaging sector. Within this fast-evolving field, Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) ( profile ) is distinguishing itself with the IzoView Breast CT Imaging System, a purpose-built 3D imaging solution engineered to enhance cancer detection accuracy, particularly in women with dense breast tissue. IzoView aligns with leading innovators such as NVIDIA Corp. (NASDAQ: NVDA), Butterfly Network Inc. (NYSE: BFLY), Lantheus Holdings Inc. (NASDAQ: LNTH), and RadNet Inc. (NASDAQ: RDNT), all of which are driving the…
The healthcare industry is experiencing a profound transformation, propelled by the accelerating adoption of artificial intelligence. While AI's potential has long been discussed, recent advancements in generative AI are now yielding tangible benefits, delivering measurable returns across clinical and administrative domains. This shift is further amplified by the emerging paradigm of 'agentic AI,' which promises [...]
Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will report third quarter 2025 financial results on October 31, 2025 before the market opens.
Butterfly Network, Inc. (“Butterfly”) (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced the appointment of John Doherty as Executive Vice President, Chief Financial Officer, effective December 8, 2025. Doherty has more than 25 years of global financial leadership experience, guiding public and private companies through major growth, transformation, and strategic transactions across the technology and telecommunications industries.
Butterfly Network shares rose 14.81% in after-hours trading on Thursday after being named to TIME's inaugural list of the World's Top HealthTech Companies for 2025.
Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound, today announced its inclusion in the first edition of the World’s Top HealthTech Companies 2025, presented by TIME and Statista Inc., the world-leading statistics portal and industry ranking provider.
Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care through portable, semiconductor-based ultrasound technology and intuitive software, today announced the appointment of Victor Ku as Senior Vice President and Chief Technology Officer (CTO). Victor will join the company in late September and will be responsible for leading Butterfly’s global technology strategy, product development, and innovation roadmap.
Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care through portable, semiconductor-based ultrasound technology and intuitive software, today announced that the full results of the POCUS for Cardiopulmonary Assessment and Resource Evaluation (POCUS-CARE) trial have been published in The Journal of the American Medical Association (JAMA).
Clipper Distributing LLC (“Clipper”), a leading distributor partner and service provider in the veterinary health market, and Butterfly Network, Inc. (“Butterfly”) (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound, announced an agreement to commercialize Butterfly’s award-winning point-of-care ultrasound devices.
Butterfly Network, Inc. (“Butterfly”, “the Company”) (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound, today announced its role in the international research study CAD LUS4TB that will evaluate the impact of AI-assisted point-of-care ultrasound (POCUS) on tuberculosis (TB) triage in under-resourced settings.
Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced its role in new research demonstrating the potential for machine learning (ML) models to support early detection of aortic stenosis (AS) using handheld ultrasound devices. The study, conducted by Tufts Medical Center and published in European Heart Journal – Imaging Methods and Practice, demonstrates that a ML model fine-tuned for use on Butterfly iQ+ devices can achieve high accuracy in identifying AS. The findings support the value of ML model development, and ultimately, are a positive step toward portable screening for earlier detection of this life-threatening condition.
First bullet in "Guidance" section should read: Revenue of $91 million to $95 million or approximately 13% growth (instead of "Revenue of $92 million to $96 million or approximately 15% growth").
